Induction Therapy for Pediatric and Adult Heart Transplantation: Comparison Between OKT3 and Daclizumab

Abstract

Daclizumab induction therapy is as efficacious as OKT3 in the prevention of early acute rejection after heart transplantation among pediatric and adult subjects. Complications related to the induction agent are significantly lower in the humanized product.